FDA alert on Valproic Acid use in pregnancy

FDA is notifying consumers and healthcare professionals about new labeling changes for valproate products (ie, valproic acid, valproate sodium, or divalproex sodium). FDA is updating the product labeling to change the pregnancy category from "D" to "X" in patients receiving valproate for migraine prophylaxis. This labeling change means valproate products are now contraindicated in pregnant patients for prevention of migraine headaches. Valproate products will continue to carry the pregnancy category D for use in seizure disorders and bipolar disorders.

LSOG 2013